Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cefprozil for · 3 trials · 1 indication
Bioequivalence based on Cmax.
Bioequivalence based on AUC0-t.
Bioequivalence based on AUC0-inf.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Cefprozil for oral suspension 250 mg/5 mL | DRUG | 1 x 250 mg/5 mL, single-dose fasting |
| CEFZIL® for Oral Suspension 250 mg/5mL | DRUG | 1 x 250 mg/5 mL, single-dose fasting |
| cefprozil | DRUG | 500 mg Tablet |
| Cefzil® | DRUG | 500 mg Tablet |
Inclusion Criteria: * All subjects selected for this study will be non-smokers at least 18 years of age. Subjects will have a BMI (body mass index) of 30 or less. * Each subject shall be given a general physical examination within 28 days of initiation of the study. Such examination includes, but i...
Cefprozil for is an investigational small molecule being developed by Teva Pharmaceutical Industries Limited (TEVA). It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied in oral suspension and tablet forms under fasting and fed conditions.
Cefprozil for is being developed by Teva Pharmaceutical Industries Limited, a company traded under the ticker TEVA. The drug is currently in Phase 1 clinical development, with all completed trials conducted in the United States.
Cefprozil for is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All three clinical trials for this drug have been completed, with a total enrollment of 91 healthy volunteers.
Cefprozil for has three completed Phase 1 clinical trials: NCT00835354 (oral suspension 250 mg/5 mL, non-fasting), NCT00835614 (oral suspension 250 mg/5 mL, fasting), and NCT00840866 (500 mg tablets under fed conditions). All trials enrolled healthy adults aged 18 years and older in the United States.
Cefprozil for is a drug being studied in healthy volunteers for bioavailability and food-effect purposes. It is developed by Teva Pharmaceutical Industries Limited and is currently in Phase 1 clinical trials. The drug is an investigational small molecule, and its development status is not yet beyond early-stage testing.